FDA Approved: EGRIFTA WR — Supplemental Application (Theratechnologies Inc.)

View source ↗

Summary

The FDA approved a supplemental application for EGRIFTA WR (tesamorelin) submitted by Theratechnologies Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hiv-associated Lipodystrophy

Drugs mentioned

• EGRIFTA WR (TESAMORELIN)

Snippet

SUPPL AP for EGRIFTA WR (TESAMORELIN)